By Dean Seal
Shares of C4 Therapeutics are trading higher Wednesday after the company said regulators cleared the investigational new drug application for its non-small cell lung cancer treatment.
The stock is up 18% at $3.35 in early trading. Shares have fallen by more than 43% since the start of the year.
The…
Read the full article here
